PFE Pfizer Inc

By Colin Kellaher

Covid-19 vaccine partners Pfizer Inc. and BioNTech SE on Wednesday said they plan to expand their collaboration in an effort to develop a potential first mRNA-based vaccine for the prevention of the common viral infection shingles.

Under the expanded pact, Pfizer would make $225 million in upfront payments to BioNTech, including $75 million in cash and an equity investment of $150 million.

The companies said they plan to use a proprietary antigen technology identified by Pfizer along with BioNTech's proprietary mRNA platform technology, which they also used in their wildly successful Covid-19 vaccine.

BioNTech is eligible to receive up to $200 million in regulatory and sales milestone payments under the shingles collaboration and would pay Pfizer $25 million for the antigen technology, the companies said.

Shingles, also known as herpes zoster virus, is a disfiguring and painful disease that affects about a third of people in the U.S. during their lifetime.

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech first launched an influenza vaccine collaboration in 2018 and began work on their Covid-19 vaccine in 2020.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 05, 2022 07:22 ET (12:22 GMT)

Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024

Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024